nodes	percent_of_prediction	percent_of_DWPC	metapath
Methyclothiazide—Hypercalcaemia—Vandetanib—thyroid cancer	0.0536	0.0547	CcSEcCtD
Methyclothiazide—Respiratory distress—Sorafenib—thyroid cancer	0.0395	0.0403	CcSEcCtD
Methyclothiazide—Pancreatitis—Vandetanib—thyroid cancer	0.0229	0.0234	CcSEcCtD
Methyclothiazide—Photosensitivity reaction—Vandetanib—thyroid cancer	0.0213	0.0218	CcSEcCtD
Methyclothiazide—Hyperglycaemia—Vandetanib—thyroid cancer	0.0211	0.0215	CcSEcCtD
Methyclothiazide—Pneumonia—Vandetanib—thyroid cancer	0.021	0.0214	CcSEcCtD
Methyclothiazide—Stevens-Johnson syndrome—Vandetanib—thyroid cancer	0.0207	0.0211	CcSEcCtD
Methyclothiazide—Erythema multiforme—Vandetanib—thyroid cancer	0.0177	0.018	CcSEcCtD
Methyclothiazide—Malnutrition—Vandetanib—thyroid cancer	0.0163	0.0166	CcSEcCtD
Methyclothiazide—Muscle spasms—Vandetanib—thyroid cancer	0.0156	0.016	CcSEcCtD
Methyclothiazide—Pancreatitis—Sorafenib—thyroid cancer	0.0155	0.0158	CcSEcCtD
Methyclothiazide—Vision blurred—Vandetanib—thyroid cancer	0.0153	0.0157	CcSEcCtD
Methyclothiazide—Pneumonia—Sorafenib—thyroid cancer	0.0141	0.0144	CcSEcCtD
Methyclothiazide—Stevens-Johnson syndrome—Sorafenib—thyroid cancer	0.0139	0.0142	CcSEcCtD
Methyclothiazide—Jaundice—Sorafenib—thyroid cancer	0.0137	0.014	CcSEcCtD
Methyclothiazide—Hypercalcaemia—Epirubicin—thyroid cancer	0.0134	0.0136	CcSEcCtD
Methyclothiazide—Thrombocytopenia—Vandetanib—thyroid cancer	0.013	0.0133	CcSEcCtD
Methyclothiazide—Hypercalcaemia—Doxorubicin—thyroid cancer	0.0124	0.0126	CcSEcCtD
Methyclothiazide—Paraesthesia—Vandetanib—thyroid cancer	0.0119	0.0122	CcSEcCtD
Methyclothiazide—Erythema multiforme—Sorafenib—thyroid cancer	0.0119	0.0122	CcSEcCtD
Methyclothiazide—Decreased appetite—Vandetanib—thyroid cancer	0.0115	0.0118	CcSEcCtD
Methyclothiazide—Glycosuria—Epirubicin—thyroid cancer	0.0115	0.0117	CcSEcCtD
Methyclothiazide—Constipation—Vandetanib—thyroid cancer	0.0114	0.0116	CcSEcCtD
Methyclothiazide—Malnutrition—Sorafenib—thyroid cancer	0.011	0.0112	CcSEcCtD
Methyclothiazide—Glycosuria—Doxorubicin—thyroid cancer	0.0106	0.0108	CcSEcCtD
Methyclothiazide—Muscle spasms—Sorafenib—thyroid cancer	0.0106	0.0108	CcSEcCtD
Methyclothiazide—Body temperature increased—Vandetanib—thyroid cancer	0.0105	0.0107	CcSEcCtD
Methyclothiazide—Hyperuricaemia—Epirubicin—thyroid cancer	0.01	0.0102	CcSEcCtD
Methyclothiazide—Leukopenia—Sorafenib—thyroid cancer	0.00983	0.01	CcSEcCtD
Methyclothiazide—Asthenia—Vandetanib—thyroid cancer	0.00953	0.00972	CcSEcCtD
Methyclothiazide—Blood uric acid increased—Epirubicin—thyroid cancer	0.00945	0.00964	CcSEcCtD
Methyclothiazide—Hyperuricaemia—Doxorubicin—thyroid cancer	0.00926	0.00945	CcSEcCtD
Methyclothiazide—Diarrhoea—Vandetanib—thyroid cancer	0.00909	0.00927	CcSEcCtD
Methyclothiazide—Anaphylactic shock—Sorafenib—thyroid cancer	0.00896	0.00914	CcSEcCtD
Methyclothiazide—Dizziness—Vandetanib—thyroid cancer	0.00878	0.00896	CcSEcCtD
Methyclothiazide—Thrombocytopenia—Sorafenib—thyroid cancer	0.00877	0.00895	CcSEcCtD
Methyclothiazide—Blood uric acid increased—Doxorubicin—thyroid cancer	0.00875	0.00892	CcSEcCtD
Methyclothiazide—Aplastic anaemia—Epirubicin—thyroid cancer	0.00872	0.00889	CcSEcCtD
Methyclothiazide—Anorexia—Sorafenib—thyroid cancer	0.00854	0.00872	CcSEcCtD
Methyclothiazide—Vomiting—Vandetanib—thyroid cancer	0.00845	0.00862	CcSEcCtD
Methyclothiazide—Rash—Vandetanib—thyroid cancer	0.00838	0.00855	CcSEcCtD
Methyclothiazide—Dermatitis—Vandetanib—thyroid cancer	0.00837	0.00854	CcSEcCtD
Methyclothiazide—Headache—Vandetanib—thyroid cancer	0.00832	0.00849	CcSEcCtD
Methyclothiazide—Pulmonary oedema—Epirubicin—thyroid cancer	0.00826	0.00843	CcSEcCtD
Methyclothiazide—Aplastic anaemia—Doxorubicin—thyroid cancer	0.00806	0.00823	CcSEcCtD
Methyclothiazide—Nausea—Vandetanib—thyroid cancer	0.00789	0.00805	CcSEcCtD
Methyclothiazide—Decreased appetite—Sorafenib—thyroid cancer	0.00779	0.00795	CcSEcCtD
Methyclothiazide—Photosensitivity—Epirubicin—thyroid cancer	0.00767	0.00783	CcSEcCtD
Methyclothiazide—Constipation—Sorafenib—thyroid cancer	0.00766	0.00782	CcSEcCtD
Methyclothiazide—Pulmonary oedema—Doxorubicin—thyroid cancer	0.00765	0.0078	CcSEcCtD
Methyclothiazide—Vascular purpura—Epirubicin—thyroid cancer	0.00753	0.00769	CcSEcCtD
Methyclothiazide—Urticaria—Sorafenib—thyroid cancer	0.00712	0.00726	CcSEcCtD
Methyclothiazide—Photosensitivity—Doxorubicin—thyroid cancer	0.0071	0.00724	CcSEcCtD
Methyclothiazide—Body temperature increased—Sorafenib—thyroid cancer	0.00708	0.00723	CcSEcCtD
Methyclothiazide—Purpura—Epirubicin—thyroid cancer	0.00699	0.00713	CcSEcCtD
Methyclothiazide—Vascular purpura—Doxorubicin—thyroid cancer	0.00697	0.00711	CcSEcCtD
Methyclothiazide—Hypersensitivity—Sorafenib—thyroid cancer	0.0066	0.00674	CcSEcCtD
Methyclothiazide—Purpura—Doxorubicin—thyroid cancer	0.00647	0.0066	CcSEcCtD
Methyclothiazide—Asthenia—Sorafenib—thyroid cancer	0.00643	0.00656	CcSEcCtD
Methyclothiazide—Orthostatic hypotension—Epirubicin—thyroid cancer	0.00615	0.00628	CcSEcCtD
Methyclothiazide—Diarrhoea—Sorafenib—thyroid cancer	0.00613	0.00626	CcSEcCtD
Methyclothiazide—Dizziness—Sorafenib—thyroid cancer	0.00593	0.00605	CcSEcCtD
Methyclothiazide—Pancreatitis—Epirubicin—thyroid cancer	0.00571	0.00583	CcSEcCtD
Methyclothiazide—Vomiting—Sorafenib—thyroid cancer	0.0057	0.00581	CcSEcCtD
Methyclothiazide—Orthostatic hypotension—Doxorubicin—thyroid cancer	0.00569	0.00581	CcSEcCtD
Methyclothiazide—Rash—Sorafenib—thyroid cancer	0.00565	0.00576	CcSEcCtD
Methyclothiazide—Dermatitis—Sorafenib—thyroid cancer	0.00565	0.00576	CcSEcCtD
Methyclothiazide—Headache—Sorafenib—thyroid cancer	0.00561	0.00573	CcSEcCtD
Methyclothiazide—Nausea—Sorafenib—thyroid cancer	0.00532	0.00543	CcSEcCtD
Methyclothiazide—Photosensitivity reaction—Epirubicin—thyroid cancer	0.00532	0.00542	CcSEcCtD
Methyclothiazide—Pancreatitis—Doxorubicin—thyroid cancer	0.00528	0.00539	CcSEcCtD
Methyclothiazide—Hyperglycaemia—Epirubicin—thyroid cancer	0.00525	0.00536	CcSEcCtD
Methyclothiazide—Pneumonia—Epirubicin—thyroid cancer	0.00522	0.00533	CcSEcCtD
Methyclothiazide—Stevens-Johnson syndrome—Epirubicin—thyroid cancer	0.00515	0.00525	CcSEcCtD
Methyclothiazide—Jaundice—Epirubicin—thyroid cancer	0.00506	0.00516	CcSEcCtD
Methyclothiazide—Photosensitivity reaction—Doxorubicin—thyroid cancer	0.00492	0.00502	CcSEcCtD
Methyclothiazide—Hyperglycaemia—Doxorubicin—thyroid cancer	0.00486	0.00496	CcSEcCtD
Methyclothiazide—Agranulocytosis—Epirubicin—thyroid cancer	0.00485	0.00494	CcSEcCtD
Methyclothiazide—Pneumonia—Doxorubicin—thyroid cancer	0.00483	0.00493	CcSEcCtD
Methyclothiazide—Stevens-Johnson syndrome—Doxorubicin—thyroid cancer	0.00476	0.00486	CcSEcCtD
Methyclothiazide—Jaundice—Doxorubicin—thyroid cancer	0.00468	0.00478	CcSEcCtD
Methyclothiazide—Agranulocytosis—Doxorubicin—thyroid cancer	0.00448	0.00457	CcSEcCtD
Methyclothiazide—Erythema multiforme—Epirubicin—thyroid cancer	0.00441	0.0045	CcSEcCtD
Methyclothiazide—Erythema multiforme—Doxorubicin—thyroid cancer	0.00408	0.00416	CcSEcCtD
Methyclothiazide—Malnutrition—Epirubicin—thyroid cancer	0.00406	0.00414	CcSEcCtD
Methyclothiazide—Muscle spasms—Epirubicin—thyroid cancer	0.0039	0.00398	CcSEcCtD
Methyclothiazide—Vision blurred—Epirubicin—thyroid cancer	0.00382	0.0039	CcSEcCtD
Methyclothiazide—Malnutrition—Doxorubicin—thyroid cancer	0.00375	0.00383	CcSEcCtD
Methyclothiazide—Agitation—Epirubicin—thyroid cancer	0.00373	0.0038	CcSEcCtD
Methyclothiazide—Vertigo—Epirubicin—thyroid cancer	0.00365	0.00372	CcSEcCtD
Methyclothiazide—Leukopenia—Epirubicin—thyroid cancer	0.00363	0.00371	CcSEcCtD
Methyclothiazide—Muscle spasms—Doxorubicin—thyroid cancer	0.00361	0.00368	CcSEcCtD
Methyclothiazide—Vision blurred—Doxorubicin—thyroid cancer	0.00354	0.00361	CcSEcCtD
Methyclothiazide—Agitation—Doxorubicin—thyroid cancer	0.00345	0.00352	CcSEcCtD
Methyclothiazide—Vertigo—Doxorubicin—thyroid cancer	0.00337	0.00344	CcSEcCtD
Methyclothiazide—Leukopenia—Doxorubicin—thyroid cancer	0.00336	0.00343	CcSEcCtD
Methyclothiazide—Anaphylactic shock—Epirubicin—thyroid cancer	0.00331	0.00338	CcSEcCtD
Methyclothiazide—Thrombocytopenia—Epirubicin—thyroid cancer	0.00324	0.00331	CcSEcCtD
Methyclothiazide—Anorexia—Epirubicin—thyroid cancer	0.00316	0.00322	CcSEcCtD
Methyclothiazide—Anaphylactic shock—Doxorubicin—thyroid cancer	0.00306	0.00313	CcSEcCtD
Methyclothiazide—Thrombocytopenia—Doxorubicin—thyroid cancer	0.003	0.00306	CcSEcCtD
Methyclothiazide—Paraesthesia—Epirubicin—thyroid cancer	0.00297	0.00303	CcSEcCtD
Methyclothiazide—Anorexia—Doxorubicin—thyroid cancer	0.00292	0.00298	CcSEcCtD
Methyclothiazide—Decreased appetite—Epirubicin—thyroid cancer	0.00288	0.00294	CcSEcCtD
Methyclothiazide—Constipation—Epirubicin—thyroid cancer	0.00283	0.00289	CcSEcCtD
Methyclothiazide—Paraesthesia—Doxorubicin—thyroid cancer	0.00275	0.00281	CcSEcCtD
Methyclothiazide—Decreased appetite—Doxorubicin—thyroid cancer	0.00266	0.00272	CcSEcCtD
Methyclothiazide—Urticaria—Epirubicin—thyroid cancer	0.00263	0.00268	CcSEcCtD
Methyclothiazide—Constipation—Doxorubicin—thyroid cancer	0.00262	0.00267	CcSEcCtD
Methyclothiazide—Body temperature increased—Epirubicin—thyroid cancer	0.00262	0.00267	CcSEcCtD
Methyclothiazide—Hypersensitivity—Epirubicin—thyroid cancer	0.00244	0.00249	CcSEcCtD
Methyclothiazide—Urticaria—Doxorubicin—thyroid cancer	0.00243	0.00248	CcSEcCtD
Methyclothiazide—Body temperature increased—Doxorubicin—thyroid cancer	0.00242	0.00247	CcSEcCtD
Methyclothiazide—CA4—neck—thyroid cancer	0.00241	0.121	CbGeAlD
Methyclothiazide—Asthenia—Epirubicin—thyroid cancer	0.00238	0.00242	CcSEcCtD
Methyclothiazide—Diarrhoea—Epirubicin—thyroid cancer	0.00227	0.00231	CcSEcCtD
Methyclothiazide—Hypersensitivity—Doxorubicin—thyroid cancer	0.00226	0.0023	CcSEcCtD
Methyclothiazide—Asthenia—Doxorubicin—thyroid cancer	0.0022	0.00224	CcSEcCtD
Methyclothiazide—Dizziness—Epirubicin—thyroid cancer	0.00219	0.00223	CcSEcCtD
Methyclothiazide—Vomiting—Epirubicin—thyroid cancer	0.00211	0.00215	CcSEcCtD
Methyclothiazide—Diarrhoea—Doxorubicin—thyroid cancer	0.0021	0.00214	CcSEcCtD
Methyclothiazide—Rash—Epirubicin—thyroid cancer	0.00209	0.00213	CcSEcCtD
Methyclothiazide—Dermatitis—Epirubicin—thyroid cancer	0.00209	0.00213	CcSEcCtD
Methyclothiazide—Headache—Epirubicin—thyroid cancer	0.00207	0.00212	CcSEcCtD
Methyclothiazide—Dizziness—Doxorubicin—thyroid cancer	0.00203	0.00207	CcSEcCtD
Methyclothiazide—CA2—neck—thyroid cancer	0.002	0.101	CbGeAlD
Methyclothiazide—Nausea—Epirubicin—thyroid cancer	0.00197	0.00201	CcSEcCtD
Methyclothiazide—Vomiting—Doxorubicin—thyroid cancer	0.00195	0.00199	CcSEcCtD
Methyclothiazide—Rash—Doxorubicin—thyroid cancer	0.00193	0.00197	CcSEcCtD
Methyclothiazide—Dermatitis—Doxorubicin—thyroid cancer	0.00193	0.00197	CcSEcCtD
Methyclothiazide—Headache—Doxorubicin—thyroid cancer	0.00192	0.00196	CcSEcCtD
Methyclothiazide—SLC12A1—head—thyroid cancer	0.00189	0.0953	CbGeAlD
Methyclothiazide—CA4—saliva-secreting gland—thyroid cancer	0.00188	0.0946	CbGeAlD
Methyclothiazide—Nausea—Doxorubicin—thyroid cancer	0.00182	0.00186	CcSEcCtD
Methyclothiazide—CA2—saliva-secreting gland—thyroid cancer	0.00156	0.0785	CbGeAlD
Methyclothiazide—CA4—trachea—thyroid cancer	0.00145	0.073	CbGeAlD
Methyclothiazide—CA1—head—thyroid cancer	0.0013	0.0655	CbGeAlD
Methyclothiazide—CA2—trachea—thyroid cancer	0.0012	0.0605	CbGeAlD
Methyclothiazide—CA4—thyroid gland—thyroid cancer	0.00115	0.0578	CbGeAlD
Methyclothiazide—CA4—head—thyroid cancer	0.00102	0.0512	CbGeAlD
Methyclothiazide—CA2—thyroid gland—thyroid cancer	0.000951	0.0479	CbGeAlD
Methyclothiazide—CA1—lymph node—thyroid cancer	0.000912	0.0459	CbGeAlD
Methyclothiazide—CA2—head—thyroid cancer	0.000844	0.0425	CbGeAlD
Methyclothiazide—CA4—lymph node—thyroid cancer	0.000713	0.0359	CbGeAlD
Methyclothiazide—CA2—lymph node—thyroid cancer	0.000591	0.0297	CbGeAlD
